Page last updated: 2024-11-06

6,7-dihydro-1,1,2,3,3-pentamethyl-4-(5h)indanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6,7-dihydro-1,1,2,3,3-pentamethyl-4-(5H)indanone: polycyclic musk fragrance; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID92292
CHEMBL ID3183584
SCHEMBL ID232766
MeSH IDM0286917

Synonyms (40)

Synonym
1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4h-inden-4-one
4h-inden-4-one, 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-
cashmeran
6,7-dihydro-1,1,2,3,3-pentamethyl-4(5h)-indanone
einecs 251-649-3
33704-61-9
FT-0664402
1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one
dtxsid8047399 ,
tox21_302677
NCGC00256636-01
dtxcid6027399
cas-33704-61-9
(+-)-cashmeran
ec 251-649-3
ccris 8406
6,7-dihydro-1,1,2,3,3-pentamethyl-4-(5h)indanone
bzr4438my4 ,
musk indanone
unii-bzr4438my4
dihydro-1,1,2,3,3-pentamethyl-4(5h)-indanone
(+/-)-cashmeran
dihydro pentamethylindanone
4(5h)-indanone, 6,7-dihydro-1,1,2,3,3-pentamethyl-
dihydro pentamethylindanone [inci]
SCHEMBL232766
1,1,2,3,3-pentamethyl-1,2,3,5,6,7-hexahydro-inden-4-one
AKOS022171974
casmierone
1,1,2,3,3-pentamethyl-2,3,6,7-tetrahydro-1h-inden-4(5h)-one
CHEMBL3183584
6,7-dihydro-1,1,2,3,3-pentamethyl-4(5h)-indanone, aldrichcpr
dpmi 10 microg/ml in cyclohexane
J-019301
CS-0210538
mfcd00216987
AS-16133
1,1,2,3,3-pentamethyl-2,3,4,5,6,7-hexahydro-1h-inden-4-one
Q1047397
1,1,2,3,3-pentamethyl-2,3,4,5,6,7-hexahydroinden-4-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency3.40810.000714.592883.7951AID1259369; AID1259392
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.00390.003041.611522,387.1992AID1159552
estrogen nuclear receptor alphaHomo sapiens (human)Potency48.55770.000229.305416,493.5996AID743079
activating transcription factor 6Homo sapiens (human)Potency0.48970.143427.612159.8106AID1159516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's1 (11.11)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.67 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.43 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]